Retraction and republication-Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Lancet Respir Med
.
2024 Apr;12(4):262-263.
doi: 10.1016/S2213-2600(24)00029-8.
Author
The Editors Of The Lancet Respiratory Medicine
1
Affiliation
1
The Lancet Respiratory Medicine, London EC2Y 5AS, UK.
PMID:
38552648
DOI:
10.1016/S2213-2600(24)00029-8
No abstract available
Publication types
Retraction of Publication